HA-1 TCR T cell therapy
Phase 1- Indications
- Post-transplant leukemia relapse
Company intelligence / Profile preview
HighPass Bio’s lead program is a Phase 1 clinical trial evaluating adoptive immunotherapy with CD8+ and CD4+ donor memory T cells transduced to express an HA‑1-specific TCR for patients with relapsed leukemia following allogeneic HSCT. Initial patients have been dosed, but the trial is currently listed as suspended. The approach aims to treat or prevent post-transplant leukemic relapse by targeting the minor histocompatibility antigen HA‑1 on leukemic cells
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HighPass Bio.